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Introduction: Ionized calcium (iCa) concentration is often used in critical care and measured using blood gas
analyzers at the point of care. Controlling and adjusting regional citrate anticoagulation (RCA) for continuous renal
replacement therapy (CRRT) involves measuring the iCa concentration in two samples: systemic with physiological
iCa concentrations and post filter samples with very low iCa concentrations. However, modern blood gas analyzers
are optimized for physiological iCa concentrations which might make them less suitable for measuring low iCa in
blood with a high concentration of citrate. We present results of iCa measurements from six different blood gas
analyzers and the impact on clinical decisions based on the recommendations of the dialysis’ device manufacturer.
Method: The iCa concentrations of systemic and post filter samples were measured using six distinct, frequently
used blood gas analyzers. We obtained iCa results of 74 systemic and 84 post filter samples from patients
undergoing RCA for CRRT at the University Medicine of Greifswald.
Results: The systemic samples showed concordant results on all analyzers with median iCa concentrations ranging
from 1.07 to 1.16 mmol/L. The medians of iCa concentrations for post filter samples ranged from 0.21 to
0.50 mmol/L. Results of >70 % of the post filter samples would lead to major differences in decisions regarding
citrate flow depending on the instrument used.
Conclusion: Measurements of iCa in post filter samples may give misleading information in monitoring the RCA.
Recommendations of the dialysis manufacturer need to be revised. Meanwhile, little weight should be given to
post filter iCa. Reference methods for low iCa in whole blood containing citrate should be established.Introduction
Regional citrate anticoagulation is recommended by the
Kidney Disease Improving Global Outcomes Clinical
Practice Guidelines for continuous renal replacement
therapy (CRRT) in critically ill patients [1]. Regional cit-
rate anticoagulation (RCA) for CRRT represents a well-
accepted alternative of anticoagulation for patients with
enhanced bleeding risk due to systemic anticoagulation
[2–4] by limiting the anticoagulation with citrate to the
extra corporeal circulation. Anticoagulation in CRRT is
achieved by administering citrate immediately after the* Correspondence: astrid.petersmann@uni-greifswald.de
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coagulant effect results from chelating ionized calcium
(iCa) with citrate in the extra corporeal circulation lead-
ing to reduced iCa concentrations. The chelated calcium
cannot act as a cofactor in the coagulation cascade. The
coagulation is distorted if iCa is below 0.5 mmol/L and
completely inhibited if the concentration drops below
0.3 mmol/L [5, 6]. When an adequate amount of citrate
is added (citrate flow) dialysis can take place through a
filter without clotting. After filtration calcium is added
(calcium flow) to the dialyzed blood in order to raise iCa
concentrations back to a physiological level and recon-
stitute coagulation. ICa concentration measurements
(Fig. 1) are recommended by the dialysis manufacturer
in samples collected after the dialysis filter (post filtericle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Sampling points for ionized calcium (iCa) concentration measurements in regional citrate anticoagulation for continuous renal replacement
therapy. Blood samples for iCa concentration measurements in systemic samples are taken in 1) and blood samples for iCa concentrations measurements
in post filter samples are taken in 2)
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ples) [7, 8].
The clinical effectiveness depends on fine-tuning of
the systemic iCa concentration, which is modified by the
calcium flow, and the post filter iCa concentration,
which is affected by the citrate flow. It is recommended
by the manufacturer (Fresenius Medical Care, Bad
Homburg, Germany) to analyze the systemic as well as
the post filter iCa concentrations [7, 8]. Based on these
iCa measurements the manufacturer advises schemes for
adjusting both citrate and calcium flows. No recommen-
dations are given by the manufacturer on methods and
instruments for iCa measurements. Many iCa measure-
ments in the core laboratory are performed using blood
gas analyzers which are often also used in point of care
testing (POCT). However, modern blood gas analyzers are
optimized for physiological iCa concentrations, e.g. blood
without additions of excessive electrolytes or extreme con-
centrations of such components. The matrix of the post
filter sample is characterized by un-physiologically high
citrate and extremely low iCa concentrations. This might
make currently available instruments less suitable for
these post filter samples and thus not fit for purpose as re-
quired by regulatory bodies and Good Laboratory Prac-
tice. This applies to current instruments whether used in
core laboratories or POCT.
The present study was triggered by a simultaneous
change of instruments in both the core laboratory and
on the wards. The laboratory, which is responsible for
the POCT devices, and the blood gas instrument manu-
facturer were unaware of the recommended measure-
ment of post filter samples. Accordingly, the blood gas
instruments were not validated for these measurements
and the CE approval did not cover this application.Method comparisons between the old and new devices
showed remarkable differences in the post-filter samples.
The systemic iCa concentration interval is targeted to
physiological concentrations (1.12–1.20 mmol/L) whereas
the post filter iCa concentration is extremely low with a
recommended target interval of 0.25–0.34 mmol/L [7, 8].
Reference methods for measuring iCa in whole blood
samples for physiological iCa concentrations have been
described [9]. Reference methods for low iCa and high cit-
rate concentrations, as in post filter samples, are lacking
so far. POCT and core laboratory iCa methods are not de-
signed nor thoroughly evaluated for these conditions. We
compared iCa concentration measurements of systemic
and post filter samples from patients undergoing RCA for
CRRT using six different commercially available blood gas
analyzers and describe the potential impact of these ana-
lytical results on clinical decisions.
Materials and methods
Six distinct blood gas instruments (GEM Premier 4000,
Instrumentation Laboratory, Bedford, USA; pHOx and
Prime, Nova Biomedical, Rödemark, Germany; ABL90,
Radiometer, Copenhagen, Denmark; Cobas b 123, Roche
Diagnostics, Mannheim, Germany; RAPID Point 500,
Siemens Healthcare Diagnostics, Eschborn, Germany)
were used to measure iCa concentrations in leftover ma-
terial from samples obtained from patients undergoing
RCA for CRRT (mulitFiltrate Ci-Ca® Continuous Veno-
Venous Hemo Dialysis, CVVHD, Fresenius Medical
Care, Bad Homburg, Germany) in the University Medicine
of Greifswald from June to July 2014. The measurement
intervals for iCa were 0.10–5.00 mmol/L (GEM4000),
0.10–2.70 mmol/L (Prime), 0.10–2.70 mmol/L (pHOx),
0.20–9.99 mmol/L (ABL90), 0.10–2.50 mmol/L (Cobas b
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ments for monitoring RRT were performed using the
ABL90 (Radiometer, Copenhagen, Denmark).
Systemic and post filter samples were used directly
after measurements for clinical purposes had been com-
pleted, if the amount of the material left was sufficient.
Sample material left was immediately brought to a
nearby separate room with the instruments evaluated in
the study. Therefore the pre-analytical phases were the
same for all study samples. The measurements on all
study instruments were completed within 10 minutes.
The samples were not divided because the same syringe
was used to feed the sample into each analyzer. The
measurements were thus carried out more or less in par-
allel. Results of this study were not made available for
patient care. The order of measurements was rotated be-
tween the blood gas analyzers according to a previously
randomized scheme.
Ethical approval by the local ethical board (University
of Greifswald; III UV 39/03) was obtained to use spare
material from anonymized routine patient samples for
evaluation and comparison purposes. For the use of
anonymized spare material no informed consent from
the patients was necessary. Statistical evaluations were
performed using Microsoft Excel (2010).
Results
A total of 218 samples (102 systemic and 116 post filter
samples) from 29 patients were included in the study. Of
these there were 74 systemic and 84 post filter samplesFig. 2 Measurements of ionized calcium illustrated as box plots for system
filter samples; upper row (red boxplots), systemic samples. Horizontal lines, re
previous publications [7, 8]with results for at least five of the devices. All internal
quality controls (IQC) for iCa in the six blood gas ana-
lyzers complied with national regulations (Guideline of
the German Medical Association on Quality Assurance
in Medical Laboratory Examinations; Rili-BAEK) with a
root mean square (a combined measure of imprecision
and bias) below 7.5 % (IQC target values >1–2.5 mmol/L)
and 14 % (IQC targets values from 0.2 to 1 mmol/L), re-
spectively [10].
Based on the samples that gave results in at least five de-
vices the systemic iCa median concentration ranged from
1.07 to 1.16 mmol/L (Fig. 2) with the median within in the
recommended target interval (1.12–1.20 mmol/L) for five
of the six devices. Post filter iCa median concentrations of
the different devices ranged from 0.21 to 0.50 mmol/L
(Fig. 2). There was only one of the six devices with a me-
dian value within the target interval of the recommenda-
tion scheme (0.24–0.35 mmol/L) [7, 8].
Differences (Δ) between instruments were calculated as
the averages of the individual samples. The maximum dif-
ference between two instruments was 0.09 mmol/L (95 %
CI 0.02 mmol/L) for systemic samples and 0.33 mmol/L
(95 % CI ± 0.01 mmol/L; median Δ 0.29 mmol/L; 0.21–
0.50 mmol/L) for post filter samples. In Fig. 3 the observa-
tions of the individual instruments are plotted against the
average results over all instruments of the same sample
for both systemic and poster filter samples.
The clinical impact of the results of all 218 samples
was evaluated according to the manufacturers’ recom-
mendations [7, 8]. Results of iCa in the systemic samplesic and post filter samples by instrument. Lower row (blue boxplots), post
spective upper and lower limits of target intervals according to
Fig. 3 Systemic and post filter measurements of ionized calcium
(iCa) concentrations. Regressions are between results from individual
instruments and the average of all results of a particular sample. The
maximum difference in the post filter group was found between the
Prime (red triangles) and the Cobas b 123 (blue squares). The other
instruments are (top to bottom, diamonds) the pHOx (gray), ABL90
(green), Rapid (light brown) and Gem4000 (yellow and black border).
Red dotted line is the equal line. The relative maximum difference in
the systematic result group was miniscule and the individual
observations indistinguishable at the present resolution
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six devices more than 80 % of the systemic iCa concen-
trations were within the recommended target interval
(1.12–1.20 mmol/L) and the next categories below
(1.05–1.11 mmol/L) and above (1.21–1.30 mmol/L;
Tables 1 and 2), respectively. For the sixth instrument
56 % of the systemic results were within these three cen-
tral intervals of the recommendation scheme.
Results of iCa in post filter samples are used to adjust
citrate flow. The percentage of post filter samples within
the recommended target interval (0.25–0.34 mmol/L)
and the next categories below (0.20–0.24 mmol/L) and
above (0.35–0.45 mmol/L) ranged from 3 to 87 %Table 1 Recommendations for change of calcium flow based on sy
percentage of study samples in each category depending on the in
Systemic iCa
(mmol/L)






>1.45 Decreased by 0.6 mmol/La 0 0
1.31–1.45 Decreased by 0.4 mmol/L 2 1
1.21–1.30 Decreased by 0.2 mmol/L 12 21
1.12–1.20 No change 38 41
1.05–1.11 Increased by 0.2 mmol/L 27 21
0.95–1.11 Increased by 0.4 mmol/L 16 11
<0.95 Increased by 0.6 mmol/La 6 4
aand inform physician(Tables 1 and 2). However, the distributions were not fo-
cused on the recommended target interval but were
asymmetric with maximum percentages in almost any
category of the scheme depending on the instrument
used. If transformed into clinical action, the iCa meas-
urement of the same post filter sample could lead to
maximal increase or maximum decrease of the citrate
flow depending on the instrument used.Discussion
RCA for CRRT represents an established procedure in
critically ill patients with contraindications for in vivo
anticoagulation [1]. In view of patient safety and per-
formance of CRRT the manufacturer Fresenius Medical
Care recommends monitoring iCa concentrations in sys-
temic and post filter samples to adjust calcium and citrate
flow. However, the recommendations do not include in-
formation on the methods or devices to be used for meas-
uring iCa concentrations. Instruments such as blood gas
analyzers are frequently used in monitoring RCA due to
their availability. While the iCa concentrations in the sys-
temic samples were within or close to the physiological
interval (1.12–1.32 mmol/L) the post filter samples were
characterized by iCa concentrations clearly below
0.5 mmol/L [11]. We evaluated iCa measurements of 102
systemic and 116 post filter samples from patients under-
going RCA for CRRT (mulitFiltrate Ci-Ca® Continuous
Veno-Venous Hemo Dialysis, CVVHD, Fresenius Medical
Care, Bad Homburg, Germany) using six different com-
mercially available blood gas analyzers.
To compensate the continuous loss of calcium and to
avoid hypocalcemia during RCA in CRRT the calcium
flow starts at 1.7 mmol calcium per liter of effluent. This
calcium flow is then increased, left unchanged or de-
creased according to the systemic iCa results. The sys-
temic iCa concentrations showed a good concordance
between the different instruments indicating that they
are suitable for controlling iCa substitution, indicating
that they are suitable for controlling iCa substitution.stemic ionized calcium (iCa) concentration in Ci-Ca® CVVHD and









0 0 0 0
0 1 2 2
11 21 19 3
49 41 51 22
31 21 17 31
6 11 10 25
3 4 2 17
Table 2 Recommendations for change of citrate flow based on post filter ionized calcium (iCa) concentration in Ci-Ca® CVVHD and
percentage of study samples in each category depending on the instrument used for iCa measurement
Post filter iCa
(mmol/L)














>0.45 Increased by 0.3 mmol/La 0 28 72 12 0 22
0.40–0.45 Increased by 0.2 mmol/L 6 24 26 21 0 11
0.35–0.45 Increased by 0.1 mmol/L 6 42 3 36 0 11
0.24–0.35 No change 30 6 0 31 23 49
0.20–0.24 Decreased by 0.1 mmol/L 42 0 0 0 28 6
0.15–0.19 Decreased by 0.2 mmol/L 16 0 0 0 17 0
<0.15 Decreased by 0.3 mmol/La 0 0 0 0 32 0
aand inform physician
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to either raise, leave unchanged or lower the citrate flow
depending on the measured concentration of iCa in post
filter samples [7]. Our results indicate that the concentra-
tion of iCa measured in post filter samples differ consider-
ably among the instruments as illustrated in Figs. 2 and 3.
Presently available technology does not allow defining a
reference method or value under post filter measuring
conditions. When this ambiguity of the results of mea-
surements is translated into clinical decisions based on
the recommendations of Fresenius Medical Care the re-
sults from the same post filter sample could vary from a
maximum increase of citrate flow (by 0.3 mmol/L) to a
maximum decrease of citrate flow (by 0.3 mmol/L) de-
pending on the instrument used. This is also underlined
by the differing medians (Fig. 2).
For low iCa in post filter samples it is important to
note that we do not know which result represents the
best estimate because there is no suitable reference
method or commutable reference material available.
The detailed scheme given by the manufacturer needs
to be adjusted according to the instrument used, and
made available to all customers. It is noteworthy that
the recommendations are based on a report referring
to results from one single patient [7, 8] using an
“ABL750” (Radiometer, Copenhagen, Denmark). Fur-
thermore, studies refer to and confirm a target interval
for post filter iCa of 0.25–0.35 mmol/L without dis-
closing the method used for the respective iCa meas-
urement [12, 13].
We therefore propose not to use post filter iCa for
controlling RCA in CRRT until a reference method has
been established, or at least a thorough evaluation of the
different measuring systems in combination with differ-
ent dialysis systems has been conducted. The maximum
average difference (0.33 mmol/L; 95 % CI ± 0.01 mmol/
L) or the median difference (Δ 0.29 mmol/L; 0.21–
0.50 mmol/L) in post filter iCa concentrations among the
investigated devices are approximately as large as the
complete interval of the recommendation scheme (Δ0.30 mmol/L; 0.15–0.45 mmol/L) given by Fresenius Med-
ical Care (Tables 1 and 2) [7, 8]. The investigated instru-
ments are optimized for physiological iCa concentrations,
which might make them less suitable for measuring the
low iCa in blood with a high concentration of citrate. It
has to be noted that post filter samples differ from whole
blood in many respects: the material is characterized by
low iCa concentrations and it contains citrate, which alters
the pH and consequently affects the binding capacity of
proteins for calcium. Furthermore, citrate might harm the
sensors in the instruments and could affect measurements
other than the iCa. As a consequence this could also harm
patients not undergoing citrate dialysis and therefore
should be subject to further studies.
From a clinical point of view RCA in CRRT can be con-
trolled by using the systemic iCa and disregarding the post
filter iCa. The post filter iCa should only be used to prove
that the blood is anticoagulated but not to control citrate
dose. Lowering citrate flow because of false low post filter
iCa concentrations would increase the risk of coagulation
in the extracorporeal circuit. Increasing citrate flow be-
cause of false high post iCa concentrations might provoke
citrate intoxication. Both are potentially life-threatening
complications in critically ill patients.
Conclusion
The recommendations of Fresenius Medical Care need
to be revised and adapted to specific instruments for iCa
concentration measurements to ensure patient safety.
Measurements of iCa in post filter samples should only
be used to prove that the blood in the extracorporeal cir-
cuit is anticoagulated but not to control citrate dose.
Reference methods for low iCa in whole blood contain-
ing citrate need to be established.
Key messages
 The recommendations of Fresenius Medical Care
need to be revised and adapted to specific
instruments
Schwarzer et al. Critical Care  (2015) 19:321 Page 6 of 6 Measurements of iCa in post filter samples should
only be used to prove that the blood in the
extracorporeal circuit is anticoagulated but not to
control citrate dose
 Reference methods for low iCa in whole blood
containing citrate should be established
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